EarLy Elimination of Fatty Acids iN hypertriglyceridemia-induced acuTe pancreatitis (ELEFANT trial) : Protocol of an open-label, multicenter, adaptive randomized clinical trial by Zádori, Noémi et al.
lable at ScienceDirect
Pancreatology 20 (2020) 369e376Contents lists avaiPancreatology
journal homepage: www.elsevier .com/locate/panEarLy Elimination of Fatty Acids iN hypertriglyceridemia-induced
acuTe pancreatitis (ELEFANT trial): Protocol of an open-label,
multicenter, adaptive randomized clinical trial
Noemi Zadori a, **, Noemi Gede a, Judit Antal a, Andrea Szentesi a, b, Hussain Alizadeh c,
Aron Vincze a, d, Ferenc Izbeki e, Maria Papp f, Laszlo Czako g, Marta Varga h,
Enrique de-Madaria i, Ole H. Petersen j, Vijay P. Singh k, Julia Mayerle l,
Nandor Faluhelyi m, Attila Miseta n, Istvan Reiber e, Peter Hegyi a, b, *
a Institute for Translational Medicine, Szentagothai Research Centre, Medical School, University of Pecs, Pecs, Hungary
b Hungarian Academy of ScienceseUniversity of Szeged, Translational Multidisciplinary Research Group, Szeged, Hungary
c Division of Hematology, First Department of Internal Medicine, University of Pecs Medical School, Pecs, Hungary
d Division of Gastroenterology, First Department of Internal Medicine, University of Pecs Medical School, Pecs, Hungary
e Division of Gastroenterology, Fejer County Saint George Teaching Hospital of the University of Pecs, Szekesfehervar, Hungary
f Department of Internal Medicine, Division of Gastroenterology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
g First Department of Internal Medicine, University of Szeged, Szeged, Hungary
h Dr. Rethy Pal Hospital, Bekescsaba, Hungary
i Department of Gastroenterology, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
j School of Biosciences, Cardiff University, Wales, UK
k Department of Medicine, Mayo Clinic, Scottsdale, AZ, USA
l Medizinische Klinik und Poliklinik II, Klinikum der Universit€at München, München, Germany
m Department of Radiology, University of Pecs, Pecs, Hungary
n Department of Laboratory Medicine, University of Pecs, Pecs, Hungarya r t i c l e i n f o
Article history:
Received 3 August 2019
Received in revised form
3 December 2019
Accepted 20 December 2019








Randomized clinical trial* Corresponding author. University of Pecs Medical
** Corresponding author. University of Pecs Medical
E-mail addresses: znoeemi@gmail.com (N. Zadori)
hussain@pte.hu (H. Alizadeh), vincze.aron@pte.hu
(L. Czako), drvargamarta@gmail.com (M. Varga), ma




1424-3903/© 2020 IAP and EPC. Published by Elseviea b s t r a c t
Introduction: Acute pancreatitis (AP) is a life-threatening inflammatory disease, with no specific phar-
macological treatment. However, concerning some etiologies, early specific intervention (such as ERCP in
biliary AP) has proven to be remarkably beneficial. Hypertriglyceridemia (HTG) induces severe pancreatic
damage by several direct (cellular damage) and indirect (deterioration of microcirculation) mechanisms.
Published data suggest that early removal of triglycerides (TGs) and toxic free fatty acids (FFAs) may be
advantageous; however, high-quality evidence is still missing in the literature.
Methods: Design: ELEFANT is a randomized controlled, multicenter, international trial testing the
concept that early elimination of TGs and FFAs from the blood is beneficial in HTG-AP. The study will be
performed with the adaptive “drop-the-loser” design, which supports the possibility of dropping the
inferior treatment arm, based on the results of the interim analysis. Patients with HTG-AP defined by TG
level over 11.3 mmol/l (1000 mg/dL) are randomized into three groups: (A) patients who undergo
plasmapheresis and receive aggressive fluid resuscitation; (B) patients who receive insulin and heparin
treatment with aggressive fluid resuscitation; and (C) patients with aggressive fluid resuscitation. Please
note that all intervention must be started within 48 h from the onset of abdominal pain. Exclusion
criteria are designed logically to decrease the possibility of any distorting effects of other diseases. The
composite primary endpoint will include both severity and mortality.School, Institute for Translational Medicine, PECS, H-7624, Szigeti út 12., Hungary,
School, Institute for Translational Medicine, PECS, H-7624, Szigeti út 12., Hungary
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N. Zadori et al. / Pancreatology 20 (2020) 369e376370Results: Our null hypothesis is that early elimination of HTG and FFAs reduces the risk of mortality and
severity of AP. Sample size calculation suggests that 495 patients will need to be enrolled in order to
confirm or reject the hypothesis with a 10% dropout, 80% power and 95% significance level. The general
safety and quality checks required for high-quality evidence will be adhered to. The study will be
organized between February 2020 and December 2025.
Conclusion: Our study would provide the first direct evidence for or against early intervention in HTG-
induced AP.
© 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.Introduction
Acute pancreatitis (AP) is a life-threatening inflammatory dis-
ease, which can be induced by several different factors, such as
alcohol, gallstones and fatty acids. Unfortunately, we do not have a
specific therapy to treat AP generally; however, in some cases we
can initiate specific interventions associated with one of the spe-
cific etiologies. Therefore, understanding our specific opportunities
in each etiology of AP is crucially important.
From among the various etiologies, hypertriglyceridemia causes
the most severe pancreatitis, and it is more likely that persistent
organ failure can occur [1e5]. Its incidence rate is continuously
rising due to worldwide changes in dietary habits and obesity as
well [6]. In fact, hypertriglyceridemia-induced acute pancreatitis
may explain almost one-third of cases of AP in certain populations
[7]. Studies suggest that acute pancreatitis due to hyper-
triglyceridemia typically occurs when TG levels are >1000 mg/dL;
>11.3 mmol/L [8,9]. Furthermore, the risk of acute pancreatitis is
increased by 4% for every 100 mg/dL increase in TGs [10]. The
assumed pathomechanism is the following: there are certain TG-
rich lipoproteins, such as very low-density lipoprotein (VLDL) and
chylomicrons. Chylomicrons are too large to penetrate the intimal
surface of the endothelium and can cause an occlusion in pancreatic
capillaries, leading to ischemia, acidosis and subsequently pancre-
atitis [11]. The second hit by triglycerides comes from their de-
rivatives: hydrolysis of the TG components of these chylomicrons
leads to free fatty acid (FFA) accumulation, which can cause cyto-
toxic injury to the pancreas. FFAs can injure the vascular endo-
thelium, ductal and acinar cells in the pancreas by stimulating
inflammatory mediators, releasing intracellular calcium, inhibiting
mitochondrial complexes I and V, and causing necrosis and
pancreatitis [12e18].
This cyclical FFA production can lead to rapid progression of
pancreatitis. It is not surprising that therapies against these toxic
mechanisms have already been tested. To break this cycle, it can be
hypothesized that TG level should be rapidly reduced. One possible
treatment modality is insulin. Insulin activates the lipoprotein
lipase, which promotes the metabolism of chylomicrons and VLDLs
[19]. The other effect of insulin is inhibition of the hormone-
sensitive lipase, which would hydrolyze the TGs in the adipocytes
to FFAs and would release them into the circulation [3]. Heparin
also stimulates lipoprotein lipase (LPL) [20], which promotes the
hydrolyzation of TGs to FFAs; however, heparin has no effect on
hormone-sensitive lipase, so it may have worsened the lipotoxicity
[18]. First, a rapid acceleration caused by heparin occurs at the level
of lipoprotein lipase, which later turns into an opposite rapid
decrease as a result of hepatic degradation. This deterioration
promotes an incremental increase in chylomicron levels because of
the depletion in the lipoprotein lipase plasma stores [3,21,22].
Therefore, heparin treatment in combination with insulin could be
considered as a treatment option since it enhances LPL activity and
is thus able to reduce serum TG and FFAs [23,24].Plasmapheresis seems to be another effective therapeutic op-
tion, in which TG-rich plasma is removed through the apheretic
machine [25]. Three different modalities of direct therapeutic
plasmapheresis are available: (1) plasma exchange (PEX), (2) dou-
ble filtration plasmapheresis (DFPP), and (3) immunoadsorption/
plasma adsorption (IA/PA). During plasmapheresis, the blood is
separated by a membrane plasma separator into plasma and cells.
The separated plasma, which is loaded with pathogenic agents
(TGs, in this case), is removed and replaced with a colloid solution,
preferably albumin [26]. With regard to DFPP, after the plasma is
isolated by a plasmaseparator, it is also fractionated by molecular
weight. Components of large molecular weight (e.g. pathogenic
substances) are eliminated while the small molecular weight
components are returned to the patients (e.g. albumin). Less
replacement fluid is needed during this procedure [27] in contrast
to IA/PA, during which no substitution fluid is required at all. After
the plasma is isolated by a plasma separator, it passes through an
absorption column, which removes the pathogenic substances
[28,29]. This kind of method is regularly used to eliminate anti-
bodies [29,30]. Currently the only technique available in Hungary to
eliminate all fatty acids is PEX. Plasmapheresis rapidly removes TGs
and chylomicron from the circulation, removing the inciting factor
and halting the further inflammation and damage to the pancreas.
PEX lowers the lipid levels drastically within hours, compared to
conservative therapy, that usually takes several days to achieve the
same reduction in TG levels. Most patients require only one session
of PEX, as it is reported, to lower TG levels by 50e80%. It has been
postulated that PEX improves HTG-AP outcomes not only by
lowering TG levels, but also by removing proinflammatory markers
and cytokines to down-regulate the inflammatory process in HTG-
AP [31,32].
However, no large multicenter, randomized clinical trials have
been performed to demonstrate the evidence-based beneficial ef-
fects of these interventions. There are no guidelines available in
pancreatology to treat HTG-AP; however, the recent American So-
ciety for Apheresis (ASFA) guidelines graded apheresis as 2C (weak
recommendation; individualized decision is necessary, unclear role
of therapy) in this condition. Other alternatives may be equally
reasonable based on data from observational studies or cases series
(category III evidence) [33]. Due to the paucity of randomized trials
or high-quality comparator, no specific recommendations can be
made, regarding the starting points or end points of PEX, but it
seems reasonable to initiate the PEX in patients with HTG-AP as
early as possible. Apheresis as a therapeutic modality needs
stronger evidence, ideally in the form of a randomized clinical trial
before consideration as a standard treatment strategy.
The main objective of this trial is to determine whether early
elimination of TGs and FFAs from the blood is beneficial to patients
with HTG-AP. Our null hypothesis is that early intervention reduces
the risk of mortality and severity of AP (from 12.7% to 4.2%). To
confirm this hypothesis, a randomized clinical trial involving all
patients with HTG-AP is needed.
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Design: ELEFANT is an international, multicenter, three-armed,
randomized controlled clinical trial with the adaptive “drop-the-
loser” design. This design allows dropping the inferior treatment
arm, based on the result of the interim analysis. Patients with HTG-
AP are randomized into three groups: (A) patients who undergo
plasmapheresis and receive aggressive fluid resuscitation; (B) pa-
tients who receive continuous IV infusion of heparin combined
with insulin (IHT) with aggressive fluid resuscitation; and (C) pa-
tients with aggressive fluid resuscitation.
The study protocol was structured in accordance with Spirit
2013 [34].
Trial organization, committees and boards
The corresponding center and designer of the ELEFANT trial is
the Center for Translational Medicine at the University of Pecs
Medical School (coordinating institution and sponsor, www.tm-
centre.org) and the Hungarian Pancreatic Study Group (HPSG-
coordinating society, www.tm-centre.org). The HPSG was estab-
lished in 2011 to strengthen research in pancreatology.
The following committees and boards will be involved:
The Steering Committee (SC) will be led by PH (principal
investigator, gastroenterologist and specialist in internal medicine
and clinical pharmacology). SCmembers from Pecs (HU) will be: NZ
(physician and full-time employee on the project), AV (gastroen-
terologist and internist) and AH (hematologist and internist) and
AS (interdisciplinary unit); Szeged (HU): LC (gastroenterologist and
internist; Debrecen: (HU) MP (gastroenterologist and internist);
Szekesfehervar (HU): FI (gastroenterologist and internist); and
Bekescsaba (HU): MV (gastroenterologist and internist). Every
center will have the opportunity to delegate one member to the SC.
Additionally, there will be independent members as well.
Furthermore, the SC will include a patient representative. Primary
supervision of the study will be provided by the SC; it will make
decisions concerning all important questions (e.g. premature
termination of the study, dropouts etc.).
The International Translational Advisory Board (ITAB) will
include three gastroenterologists (EM, VPS and JM) and a basic
scientist (OHP). The task of the ITAB is to regularly monitor the trial
and to provide recommendations to the SC.
The study was designed by the SC and ITAB. It was supported by
the University of Pecs Medical School. The sponsor was not asso-
ciated with the design of the trial and will have no access to the
randomization codes or the data.
To comply with current ethical regulations, the study will have
an independent physician and safety manager.
Study population
All patients with HTG-AP will be informed regarding the pos-
sibility of taking part in the ELEFANT trial. After signed informed
consent, participants will be randomized into three groups if they
meet all the inclusion criteria and no exclusion criteria (Fig. 1.).
Inclusion criteria
The inclusion criteria are: (1) age 18e80 years; (2) diagnosed AP
on the basis of the “2 out of 3” criteria in the IAP/APA guidelines
[35]: (a) upper abdominal pain; (b) serum amylase or lipase >3x
upper limit of normal range; (c) characteristic findings on pancre-
atic imaging; (3) HTG is diagnosed: if the blood TG level is at least
1000 mg/dL (11.3 mmol/L); and (4) signed informed consent.Exclusion criteria
The exclusion criteria are: (1) pregnancy or breast feeding; (2)
any of the interventions is not available within 48 h calculated from
the start of abdominal pain; (3) any of the interventions can not be
started within 12 h calculated from the venepuncture, which pro-
vided the blood sample for HTG analysis (4) coma; (5) malignancy;
(6) early ARDS; (7) renal failure; (8) allergy to insulin or heparin; (9)
chronic pancreatitis; (10) hospitalization before admission; (11)
any reasons contraindicating plasmapheresis: severe active
bleeding or disseminated intravascular coagulation (hematocrit
level <20%), other forms of coagulopathy; hemodynamic insta-
bility; potassium plasma levels <3.5 mEq/L, sepsis, allergy to al-
bumin, chronic heart failure (NYHA Grade II or more or ejection
fraction lower than 50%) or symptoms of fluid overload at recruit-
ment or long QT syndrome.
Sample size
Sample size calculation was based on a cohort analyses of 716
patients, of which 219 had elevated TG levels (unpublished data
yet). Our data indicated that the combined rate of severe AP and
mortality is significantly higher in HTG-induced AP vs. other eti-
ologies of AP (12.7% vs. 4.2%, respectively). It is hypothesized that
either plasmapharesis or IHT reduces HTG- and FFA-induced
pancreatic damage with equal effectiveness. In order to detect
this 66% relative risk reduction, it will be necessary to recruit a
sample size of 495 subjects using a 10% dropout rate with 80%
power at 95% significance level.
Time of randomization
Patients meeting all inclusion criteria and no exclusion criteria
can be randomized after signed informed consent.
Randomization method
A randomization list will be generated by a computer program
and will form the basis for numbered sealed envelopes containing
the randomization information. After randomization, the data
generated in the episode will be uploaded to the electronic case
report form by the administrator.
Allocation will occur based on assembled randomization lists
designed individually for each recruiting medical center. The In-
dependent Data Management Board (IDMB) will prepare the
sequence of distribution with variable block lengths with an allo-
cation ratio of 1:1:1.
Blinding: Trial participants, care providers and outcome asses-
sors will be blinded until the allocation to prevent patients being
assigned to Groups A, B, and C. From assignment to intervention,
blinding cannot be provided considering the study characteristics.
The allocation sequence is blinded only to data analysts who are
completely independent of the medical team (decision making)
and data collection.
Study duration
The planned starting date of the study is February 2020, and the
planned finishing date is December 2025.
Endpoints
Primary endpoint. The primary endpoint is a composite
endpoint, which is based on the summation of cases with severe AP
or mortality (this latter includes cases only with mild or moderate
Fig. 1. Flow chart of participants according to the SPIRIT 2013 statement.
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mined according to the revised Atlanta Classification (RAC) [36].
Secondary endpoints. The following secondary endpoints will
be analysed: (1) serum TG level; (2) serum albumin level; (3) serum
Ca level; (4) pain according to the visual analogue scale 1, 2 and 3
days after randomization; (5) C-reactive protein serum levels; (6)
leukocyte count; (7) length of hospital stay; (8) need for ICU
admission; (9) length of ICU stay; (10) organ failure (divided into
transient and persistent organ failure according to the RAC defini-
tions); (11) complications of plasmapheresis; and (12) cost calcu-
lation. Notably, only direct costs will be calculated, which include
all medications, services, salaries of healthcare professionals,
equipment and day care costs.
Intervention
In this study, plasmapheresis or IHT with aggressive fluid
resuscitation will be the interventions. Patients will be randomized
into Group A, B or C (Fig. 2).
In Group A, patients will undergo plasmapheresis by plasmaexchange after randomization (as soon as possible after admission).
It is very important that the patients be hydrated before the pro-
cedure. Ringer’s lactate will be administered with 5e10 mL/kg/h
[37]. Of the three types of plasmapheresis noted above, we will use
PEX.
Before the procedure the following items will be checked: 1. the
blood test results (potassium, magnesium and total calcium, clot-
ting parameteres). If the serum calcium level is low, calcium
replacement is necessary (aim is > 2 mmol/L). 2. get an accurate
weight. After that the amount of plasma to be replaced will be
calculated by the machine.
The intervention is usually carried out using an automated
blood cell separator to ensure fluid balance and maintain a normal
plasma volume. Patients will be administered a high flow central
venous catheter. 1e1.5 plasma volumes (30e60 mL/kg) will be
removed at each cycle. It will be replaced with isotonic 5.0% human
albumin solution in order to avoid hyperalbuminaemia [38]. The
amount of single blood volume is calculated by the machine based
on sex, height, body weight and hematocrit level. Greater volumes
can be exchanged at consultant discretion.
Fig. 2. Schedule of enrolment, interventions and assessments according to the SPIRIT 2013 statement.
Patients are randomized into three groups: (A) patients who undergo plasmapheresis and receive aggressive fluid resuscitation; (B) patients who recieve insulin and heparin
treatment with aggressive fluid resuscitation; and (C) patients with aggressive fluid resuscitation. Form A contains all of the parameters recorded on admission. The three B forms
contains the information about the procedures (B1 e plasmapheresis, B2 e IHT, B3 e fluid therapy) and data, which are gathered every day during hospitalization. Form C contains
data collected at discharge from the hospital.
*from the beginning of the abdominal pain
N. Zadori et al. / Pancreatology 20 (2020) 369e376 373We will use citrate over heparin as an anticoagulant because
literature data suggest that citrate is associated with lower mor-
tality [39,40]. The colloid solution, with which the plasma will be
replaced, will be two-thirds 5% human albumin and one-third
physiological salt solution. There are no available studies which
compare the replacement fluids. However, there is one review
which reported that adverse events are more common when
plasma is used instead of albumin [41].
Replacement flow rate can be increased to reduce the duration
of the therapy. In patients receiving citrate anticoagulation, ionised
calcium levels should be monitored and replaced periodically.
Arterial blood gas, serum ionised calcium will be measured before
and during the process, at 30 min, 1 h, 2 h and again hourly and at
end of PE. We will administer 5 mL IV calcium to the patients
continuously after every liter of plasma, because one of the
frequently occurring adverse effects of plasmapheresis is numb-
ness, which can be relieved by administering calcium.
After each cycle of plasmapheresis, we will measure the TG
concentration. We will discontinue apheresis when the TG level
is < 5.6mmol/L.Wewill also check FBC and coagulation parameters
post plasma exchange.In Group B, patients will receive initial aggressive fluid resus-
citation, just like in group A. An intravenous (IV) infusion of regular
insulin and a subcutaneous (SC) injection of low-molecular-weight
heparin (LMWH) will be given, while closely monitoring the blood
sugar level (every hour) and prothrombin time (PI) (every 12 h). If
the blood sugar level is between 8.3 mmol/l and 11.1 mmol/l [3], we
will administer 5% dextrose infusion to prevent hypoglycemia. The
rate of insulin infusion will be 0.1 units/kg/hour, and the dose of
LMWH (enoxaparin) is 4000 IU every 12 h. Published data suggest
that IV insulin is more effective than subcutaneous insulin and it is
much easier to titrate [42e44]. We will monitor the serum TG level
every 12 h, and when it is normalized, IHT will be stopped.
In Group C, patients will receive just the aggressive intravenous
fluid therapy. Please note that currently there are no evidence-
based recommendations to treat HTG-AP.
Groups A, B and C will receive standard general treatment for AP
based on the IAP/APA guidelines [37].
Monitored parameters during hospitalization
Laboratory tests and physical examinations will be performed
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measured at the time of admission and right after the intervention,
then 6,12,24,48,72 h after that. During IHT, blood sugar will be
closely monitored (every hour), and prothrombin time (PI) will be
determined every 12 h. In addition, a broad range of data will be
assembled during the study (e.g. medical history, other laboratory
tests (obligatory and recommended paramaters), diagnostic imag-
ing, therapy and interventions, if necessary). Form A contains all of
the parameters recorded on admission (Supplementary File 1). The
three B forms contains the information about the procedures (B1 e
plasmapheresis, B2 e IHT, B3 e fluid therapy) and data, which are
gathered every day during hospitalization (Supplementary File 2, 3,
4). Form C contains data collected at discharge from the hospital
(Supplementary file 5). Data collection on the case report form
(CRF) will occur electronically (see Data management).
Discharge of patients
Uniformization of the length of hospital stay is necessary to
avoid bias. Patients will be counted as discharged from the hospital/
study when (1) oral feeding is tolerated for 24 h; (2) CRP level
is< 50mg/L; (3) abdominal pain has been completely resolved; and
(4) no other pancreatitis-related complication requiring hospitali-
zation is detected. Before the patient is discharged, either an ul-
trasonography (US) or computer tomography (CT) scan must be
performed. A CT scan might be chosen if the result of the discharge
US scan is uncertain or if local complications are predicted. In order
to standardize US scans, sonographers will be instructed according
to the trial requirements including the pre-defined assessment
scheme (see form C) which usage is compulsory.
Data management and statistical analyses
Data handling
Data will be handled by the IDMB. Electronic CRFs (eCRFs) will
be used. The Investigator will ensure that the data in the eCRFs are
accurate, complete and legible. Detailed data flowwill be described
in a Data Management Plan (DMP). Data from completed eCRFs will
be validated under the direction of the Data Manager on the IDMB
according to a Data Cleaning Plan (DCP). Any missing, implausible
or inconsistent recordings in the eCRFs will be referred back to the
Investigator using a data query form (DQF) and will be documented
for each individual subject before clean file status is declared. All
changes to eCRFs will be recorded. Before Database Lock, the Data
Review Meeting will decide and document necessary steps related
to any issue in the database and define the analysis sets. Members
of the Data Review Meeting are a delegated investigator, biostat-
istician and data manager. Adverse events will be coded using
MedDRA in accordance with GCP, GLP, FDA 21CFR Part 11 and other
relevant regulatory requirements.
Statistical analysis
Descriptive statistics e mean, median, standard deviation,
quartiles and relative frequencye the c2 test, Z test with Bonferroni
correction (categorical variables), relative risk (dichotomous vari-
ables), ANOVA (continuous variable) in the case of normal distri-
bution, and KruskaleWallis test in the absence of a normal
distribution will be performed. Affiliated statistical analyses will be
performed with an error probability of 0.0294 (type I error
probability).
Safety Analysis Set (SAS, all patients enrolled in the study), Per
Protocol Set (PPS, all enrolled patients who finished the study
conforming to the requirements of the study protocol) andIntention to Treat (ITT, all randomized participants who start on a
treatment, excluding consent withdrawals) will be performed.
Baseline patient and disease characteristics will be analysed using
descriptive analysis. Demographic and baseline characteristics will
be summarized for the overall study population. Descriptive sta-
tistics for both the primary and secondary parameters will be
analysed similarly.
Withdrawal of a subject from PPS
Any participants/investigators and the IDMB can submit rec-
ommendations for dropouts from the PPS group with reasons
provided to the SC. All recommendations will be filed. The SC will
discuss all the information, and, if the alteration in the protocol is
expected to have any bearing on the interventions and outcomes of
the study, the patient will not be included in the final per-protocol
analysis. Automatic dropout from the per-protocol group shall be
ordered if: (1) any of the exclusion criteria are diagnosed during the
course of AP; (2) parameters required for answering the primary
endpoints are missing; (3) serious medical reasons not related to
pancreatitis occur (e.g. accidents and stroke); or (4) a serious
adverse effect occurs.
Premature termination of the study: In the interests of patient
safety, an interim analysis will be conducted after 83 patients have
completed the study in each treatment arm. We will calculate
statistical power for the primary endpoints which will decide
whether additional subjects should be enrolled. If no more subjects
are needed, early stopping will be applied. We will test our hy-
potheses both in an interim and final analysis. For this reason, the
p-value will be adjusted to diminish the probability of type I error.
Therefore, the corrected level of significance (p-value) will be
0.0294.
The following rules will be applied:
1) If any of the groups are significantly (p < 0.0294) less effective
than the others and it is already visible that there is no hope for
ascertaining a significant difference between the other two
groups, the study will be stopped.
2) If any of the groups are significantly (p < 0.0294) less effective
than the others and it is already visible that there is hope of
ascertaining a significant difference between the other two
groups, the inferior treatment will be dropped and the study
will be continued with the rest of the two arms only.
3) If any of the groups are significantly (p < 0.0294) more effective
than the others, the study will be stopped.
The IDMB will perform an independent assessment of trial-
related documents and activities with the aim of ensuring respect
for subjects’ right, safety and well-being and to guarantee the
plausibility of clinical data. Similarity of groups at baseline will also
be checked. The study will be discontinued if the difference be-
tween the planned number of patients and the actual number is
higher than 60% within one year. The IDMB will report to the SC.
Centers: The trial will be launched in five Hungarian (Szeged,
Debrecen, Pecs, Bekescsaba and Szekesfehervar) and 2 other Eu-
ropean (Germany, Spain) centers. In addition, ELEFANT will be
opened to other centers as well. In all cases, the IDMB will conduct
an audit of the center and will report to the SC. The SC maintains
the right to decide whether a center meets the required quality
standards to join the study. The full protocol will be publicly
available in an open access journal.
Publication policy: We would like to publish the results in an
internationally highly recognized journal. Centers can nominate an
author after every 20 patients.
Patient and Public Involvement: This pre-study protocol
N. Zadori et al. / Pancreatology 20 (2020) 369e376 375contains no results and data; therefore, patients and or the public
were not involved.
Safety
Although plasmapheresis is relatively safe, adverse events or
serious adverse events can occur, and patients require careful
observation during the procedure. Expected adverse events are
listed below (see Table 1) [45]. Any change in the patient’s status
should prompt discontinuation of the PE procedure and evaluation
of the cause of the symptoms. In this trial, the IDMB will examine
safety variables after 30 patients have completed the study proto-
col. Moreover, investigators will report adverse or serious adverse
events on a separate form, which must be sent to the IDMB and SC.
The SC will discuss it, and, if the adverse effect is confirmed, it will
be reported to the relevant institutional and national ethics com-
mittee (http://www.ett.hu/tukeb.htm).
Additional information and future plan
Blood samples (serum and plasma) from every patient will be
stored. These samples can be used to analyse laboratory parameters
later if required (e.g. due to an earlier failed measurement) and to
build a biobank for future clinical studies. All the participants will
be granted informed consent accordingly. The samples will be
stored in a 80 C freezer. A follow-up study (ELEFANT PLUS) is
under construction to follow up patients for up to 5 years after
enrollment in the study. We also intend to publish the study
protocol.
Discussion
HTG causes the most severe pancreatitis from among the
different etiologies [1e5]. Preclinical research and clinical data
suggest that FFAs, a TG derivative, are toxic agent which damage
the pancreas through several direct (ATP depletion and mito-
chondrial damage) and indirect (ischemia) mechanisms [11e17].
Our main hypothesis is that elimination of FFAs from the blood
improves the severity and mortality of HTG-AP. Literature dataTable 1
Overview of adverse events related to plasmapheresis.
Overview of adverse events





















a The event rate for hypocalcemia will be collected; however, it cannot be
determined whether hypocalcemia is an additional etiological factor or a compli-
cation of HTG-induced AP.suggest that early removal of FFAs and TGs from the blood could be
beneficial; however, there is no high-quality evidence for this
statement [46]. ELEFANT is designed to provide the first evidence
for or against early intervention in HTG-AP.Declaration of competing interest (COI)
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FFA free fatty acid
ITAB International Translational Advisory Board
IDMB Independent Data Management Board
VLDL very low density lipoprotein
LPL lipoprotein lipase
PE plasma exchange
DFPP double filtration plasmapheresis
IA/PA immunoadsorption/plasma adsorption
ASFA American Society for Apheresis
IHT insulin e heparin treatment
HPSG Hungarian Pancreatic Study Group
SC Steering Committee
ARDS acute respiratory distress syndrome
NYHA New York Heart Association
RAC Revised Atlanta Classification
ICU intensive care unit
IV intravenous
LMWH low molecular weight heparin
INR international normalized ratio
CRF case report form
DMP data management plan
DCP data cleaning plan
DQF data query form
SAS safety analysis set
PPS per protocol set
ITT intention to treat
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